Stay updated on Pembrolizumab in HR-Competent & Deficient Tumors Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in HR-Competent & Deficient Tumors Clinical Trial page.

Latest updates to the Pembrolizumab in HR-Competent & Deficient Tumors Clinical Trial page
- CheckyesterdayChange DetectedThe ClinicalTrials.gov footer revision label changes from v3.8.0 to v3.8.1, while the study record content remains unchanged.SummaryDifference0.1%

- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedThe record displays details for the pembrolizumab study, including its completed status, eligibility criteria, treatment plan, outcome measures, study locations, and results-related information.SummaryDifference45%

- Check22 days agoChange DetectedThe footer revision identifier changes from v3.7.2 to v3.8.0; the page continues to display a 403 Forbidden error instead of the study record.SummaryDifference0.2%

- Check29 days agoChange DetectedA site-wide notice announces NIH’s transition from using “Artificial Intelligence” to “Super Intelligence” terminology and links to transition updates and FAQs.SummaryDifference1%

- Check36 days agoChange DetectedThe site footer now displays revision v3.7.2 instead of v3.7.1.SummaryDifference0.2%

- Check43 days agoChange DetectedThe footer revision changes from v3.7.0 to v3.7.1. The page continues to display a 403 Forbidden error.SummaryDifference0.2%

Stay in the know with updates to Pembrolizumab in HR-Competent & Deficient Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in HR-Competent & Deficient Tumors Clinical Trial page.